Aquestive Therapeutics (AQST Quick QuoteAQST - Free Report) reported $14.45 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 65.7%. EPS of -$0.07 for the same period compares to -$0.24 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $10.84 million, representing a surprise of +33.22%. The company delivered an EPS surprise of +50%, with the consensus EPS estimate being -$0.14.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Aquestive Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Manufacture and supply revenue: $8.79 million compared to the $8.24 million average estimate based on two analysts. The reported number represents a change of +22.2% year over year.
• Revenues- Co-development and research fees: $0.26 million versus $0.4 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -38.3% change.
• Revenues- License and royalty revenue: $5.4 million versus $1 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +582.9% change.

View all Key Company Metrics for Aquestive Therapeutics here>>>

Shares of Aquestive Therapeutics have returned +0.2% over the past month versus the Zacks S&P 500 composite's +8.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.